高级检索
雍琴, 岳瀚勋, 石敏, 黄仕琴, 赵轩, 余娴. pH响应性PTEN/PLGA-(HE)10-MAP纳米粒的构建及体外评价[J]. 中国药科大学学报, 2021, 52(3): 301-310. DOI: 10.11665/j.issn.1000-5048.20210306
引用本文: 雍琴, 岳瀚勋, 石敏, 黄仕琴, 赵轩, 余娴. pH响应性PTEN/PLGA-(HE)10-MAP纳米粒的构建及体外评价[J]. 中国药科大学学报, 2021, 52(3): 301-310. DOI: 10.11665/j.issn.1000-5048.20210306
YONG Qin, YUE Hanxun, SHI Min, HUANG Shiqin, ZHAO Xuan, YU Xian. Construction and in vitro evaluation of pH-responsive and tumor-targeted PTEN/PLGA-(HE)10-MAP nanoparticles[J]. Journal of China Pharmaceutical University, 2021, 52(3): 301-310. DOI: 10.11665/j.issn.1000-5048.20210306
Citation: YONG Qin, YUE Hanxun, SHI Min, HUANG Shiqin, ZHAO Xuan, YU Xian. Construction and in vitro evaluation of pH-responsive and tumor-targeted PTEN/PLGA-(HE)10-MAP nanoparticles[J]. Journal of China Pharmaceutical University, 2021, 52(3): 301-310. DOI: 10.11665/j.issn.1000-5048.20210306

pH响应性PTEN/PLGA-(HE)10-MAP纳米粒的构建及体外评价

Construction and in vitro evaluation of pH-responsive and tumor-targeted PTEN/PLGA-(HE)10-MAP nanoparticles

  • 摘要: 构建一种pH响应性细胞穿膜肽(cell-penetrating peptides,CPPs)修饰的载抑癌基因第10号染色体同源缺失性磷酸酯酶-张力蛋白(PTEN)质粒DNA的纳米粒PTEN/PLGA-(HE)10-MAP,探讨其基因递送和体外靶向抗肿瘤作用。采用双乳化-溶剂挥发法制备载PTEN质粒DNA的聚乳酸-羟基乙酸共聚物(PLGA)纳米粒PTEN/PLGA;利用酰胺缩合反应将pH响应性组氨酸-谷氨酸(HE)重复寡肽与模型两亲性多肽(MAP)的重组体(HE)10-MAP偶联至PLGA纳米粒表面,得到纳米粒PTEN/PLGA-(HE)10-MAP。以粒径、Zeta电位以及包封率与载药量为指标对其进行表征分析;通过考察其细胞毒性、细胞摄取,以及靶向转染真核表达质粒和抗肿瘤细胞增殖的能力,分析其作为目的基因靶向递送系统的可行性。结果显示,制备的纳米粒粒径为(266.5 ± 2.86) nm,包封率为(80.6 ± 6.11)%,在pH 7.4、7.0和6.5条件下Zeta电位分别为-(6.7 ± 0.26) mV、 +(0.7 ± 0.22) mV和+(37.5 ± 0.85) mV;未载质粒DNA的空载体纳米粒PLGA-(HE)10-MAP在肿瘤和正常细胞中的细胞毒性试验显示细胞存活率均在80%以上,制备的纳米粒可以被细胞摄取表达,且具有pH靶向抑制肿瘤细胞增殖的作用,在肿瘤的基因治疗中具有一定的应用前景。

     

    Abstract: To construct PTEN/PLGA-(HE)10-MAP nanoparticles, which encapsulated PTEN plasmid DNA and combined with the pH-responsive cell-penetrating peptides (CPPs), and to investigate their effects of gene delivery and anti-tumor targets in vitro. Poly (lactic-co-glycolic acid) (PLGA) nanoparticles loaded with PTEN plasmid DNA were prepared by double emulsification-solvent evaporation method. PTEN/PLGA-(HE)10-MAP nanoparticles were prepared by coupling the histidine-glutamic acid-model amphipathic peptide nanocomplex (HE)10-MAP to the surface through amide condensation reaction. Particle size, Zeta potential, encapsulation rate and drug loading were tested to characterize the nanoparticles. By analyzing the cytotoxicity, cellular uptake, targeted transfection of eukaryotic expression plasmids and anti-tumor cell proliferation, the feasibility as a targeted gene delivery system were evaluated. The particle size of PTEN/PLGA-(HE)10-MAP nanoparticles was (266.5 ± 2.86) nm, with the encapsulation efficiency (80.6 ± 6.11)%. Zeta potentials were -(6.7 ± 0.26) mV, +(0.7 ± 0.22) mV and +(37.5 ± 0.85) mV at pH 7.4, 7.0 and 6.5, respectively. In the cytotoxicity test, the cell survival rates of tumor and normal cells were above 80%.Non-loading PLGA-(HE)10-MAP nanoparticles showed no obvious cytotoxicity. The results of cellular uptake experiments showed that PTEN/PLGA-(HE)10-MAP nanoparticles were more readily taken up by cells.The results of CCK-8 showed that the nanoparticles could pH-specifically inhibit proliferation of tumor cell in vitro.And PTEN/PLGA-(HE)10-MAP nanoparticles may be applied in tumor gene therapy.

     

/

返回文章
返回